Genmab A/S (NASDAQ:GMAB) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Genmab A/S (NASDAQ:GMAB) have earned an average recommendation of “Moderate Buy” from the thirteen research firms that are covering the stock, MarketBeat reports. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $45.20.

GMAB has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Genmab A/S in a report on Tuesday, August 20th. HC Wainwright reaffirmed a “buy” rating and set a $50.00 price target on shares of Genmab A/S in a report on Friday, September 20th. BTIG Research lifted their price objective on Genmab A/S from $46.00 to $47.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Redburn Atlantic initiated coverage on Genmab A/S in a report on Tuesday, October 8th. They set a “buy” rating on the stock. Finally, Royal Bank of Canada upgraded shares of Genmab A/S from a “sector perform” rating to an “outperform” rating in a research note on Monday, July 15th.

Genmab A/S Trading Down 0.8 %

Shares of NASDAQ:GMAB opened at $23.53 on Friday. The stock has a fifty day simple moving average of $26.08 and a two-hundred day simple moving average of $27.32. Genmab A/S has a 12-month low of $23.24 and a 12-month high of $33.60. The stock has a market capitalization of $15.57 billion, a price-to-earnings ratio of 19.45, a PEG ratio of 0.71 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last posted its quarterly earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.07). Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. The company had revenue of $779.50 million during the quarter, compared to analysts’ expectations of $734.60 million. As a group, equities research analysts predict that Genmab A/S will post 1.27 EPS for the current year.

Institutional Trading of Genmab A/S

A number of large investors have recently added to or reduced their stakes in GMAB. Russell Investments Group Ltd. increased its position in Genmab A/S by 137.7% in the first quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock worth $28,000 after purchasing an additional 544 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Genmab A/S by 194.0% in the 1st quarter. GAMMA Investing LLC now owns 1,135 shares of the company’s stock worth $34,000 after buying an additional 749 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new stake in shares of Genmab A/S in the 1st quarter worth about $43,000. Barometer Capital Management Inc. purchased a new stake in shares of Genmab A/S during the 4th quarter valued at about $121,000. Finally, Headlands Technologies LLC lifted its holdings in shares of Genmab A/S by 1,702.8% in the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock valued at $129,000 after acquiring an additional 4,853 shares during the last quarter. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.